Reduced p53 tumor suppressor function and constitutive activation of BCL6 oncoprotein may represent alternative oncogenic mechanisms by which CBP/p300 mutations contribute to DLBCL transformation. The gene discussed is EP300; the disease is diffuse large B-cell lymphoma.